HomeARWR • NASDAQ
add
Arrowhead Pharmaceuticals Inc
Previous close
$20.84
Day range
$20.62 - $21.25
Year range
$17.05 - $39.83
Market cap
2.63B USD
Avg Volume
1.19M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 176.14M | 48.61% |
Net income | -170.79M | -65.91% |
Net profit margin | — | — |
Earnings per share | -1.38 | -43.75% |
EBITDA | -171.36M | -72.35% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 434.47M | -2.23% |
Total assets | 883.76M | 11.05% |
Total liabilities | 544.78M | 31.63% |
Total equity | 338.97M | — |
Shares outstanding | 124.32M | — |
Price to book | 7.83 | — |
Return on assets | -47.89% | — |
Return on capital | -52.16% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -170.79M | -65.91% |
Cash from operations | -115.42M | -455.51% |
Cash from investing | 6.95M | 170.16% |
Cash from financing | 50.39M | 4,335.48% |
Net change in cash | -58.30M | -96.81% |
Free cash flow | -69.97M | -75.86% |
About
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
525